Rhythm Pharmaceuticals, Inc.RYTMNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +72.61% | +25.94% | +66.80% | +54.28% | +36.87% |
| Gross Profit Growth | +81.15% | +25.46% | +64.40% | +55.66% | +37.87% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +4.03% | +4.85% | +4.38% | +5.11% | +8.57% |
| Weighted Average Shares Diluted Growth | +4.03% | +4.85% | +4.38% | +5.11% | +8.57% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +24.52% | +21.30% | +48.44% | +71.11% | +40.89% |
| Inventory Growth | +117.31% | +127.06% | +57.35% | -100.00% | +37.42% |
| Asset Growth | +17.89% | +49.50% | -2.39% | +39.42% | +22.67% |
| Book Value per Share Growth | -6.82% | +152.59% | +0.00% | -7.28% | -22.16% |
| Debt Growth | +212.54% | +277.25% | +6202.50% | +3647.02% | +6158.84% |
| R&D Expense Growth | +37.72% | -71.22% | +40.95% | +21.34% | +2.10% |
| SG&A Expenses Growth | +17.78% | +13.68% | +26.18% | +48.19% | +50.75% |